Discounts on canagliflozin, an SGLT2 inhibitor used to treat type 2 diabetes, are available through various avenues, including manufacturer programs and third-party discount cards [1].
How can I get a discount on canagliflozin?
Savings on canagliflozin can be accessed through discount cards provided by the drug's manufacturer, such as those available from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) [1]. These programs often target commercially insured patients who meet certain eligibility requirements. Additionally, independent websites and discount card providers offer coupons that can reduce out-of-pocket costs for the medication [1]. For those without insurance, exploring patient assistance programs or comparing prices across different pharmacies can also lead to savings.
How much does canagliflozin typically cost?
The retail price of canagliflozin can vary significantly depending on the dosage, quantity, and pharmacy. Without insurance or discount programs, a month's supply can cost several hundred dollars. However, the actual cost to patients often decreases considerably when utilizing manufacturer coupons, pharmacy discount cards, or insurance copays [1].
When does canagliflozin's patent expire?
The patent landscape for canagliflozin is complex, with multiple patents covering different aspects of the drug, including its composition, method of use, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiration dates, which are crucial for understanding when generic versions might become available [2]. Generic entry typically occurs after the expiration of key patents, potentially leading to lower prices.
Are there generic versions of canagliflozin available?
As of late 2023, generic versions of canagliflozin are not widely available in the United States. The availability of generics depends on patent expirations and any subsequent legal challenges or agreements. Once key patents expire and regulatory approval is obtained for generic formulations, lower-cost alternatives are expected to emerge.
What are the alternatives to canagliflozin for diabetes treatment?
Canagliflozin belongs to the class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. Other SGLT2 inhibitors available for type 2 diabetes management include empagliflozin and dapagliflozin [3]. Other classes of diabetes medications also exist, such as metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and insulin, each with different mechanisms of action and potential benefits [3]. The choice of an alternative depends on individual patient needs, comorbidities, and treatment goals.
What is the mechanism of action for canagliflozin?
Canagliflozin works by inhibiting SGLT2, a protein found in the kidneys responsible for reabsorbing most of the glucose filtered from the blood back into the body. By blocking SGLT2, canagliflozin reduces glucose reabsorption, leading to increased glucose excretion in the urine. This mechanism helps lower blood glucose levels in individuals with type 2 diabetes [4].
What clinical trials have been conducted on canagliflozin?
Canagliflozin has been evaluated in numerous clinical trials assessing its efficacy and safety in managing type 2 diabetes and its associated cardiovascular and renal complications. Key trials have demonstrated its ability to improve glycemic control, reduce the risk of cardiovascular events, and slow the progression of kidney disease in certain patient populations [4][5].
What are the potential side effects of canagliflozin?
Common side effects associated with canagliflozin include urinary tract infections, genital yeast infections, and increased urination [6]. More serious, though less common, side effects can include diabetic ketoacidosis (especially in individuals with type 1 diabetes or when carbohydrate intake is severely restricted), dehydration, kidney injury, and a rare but severe infection of the genital area known as Fournier's gangrene [6][7]. Patients should discuss potential risks and benefits with their healthcare provider.
Who manufactures canagliflozin?
Canagliflozin is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1]. The drug is marketed under the brand name Invokana [3].
Sources:
[1] https://www.invokana.com/savings-and-support
[2] https://www.drugpatentwatch.com/
[3] https://www.drugs.com/diabetes.html
[4] https://www.invokana.com/hcp/mechanism-of-action
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1615869
[6] https://www.invokana.com/hcp/side-effects
[7] https://www.invokana.com/patient/side-effects